Neuren Pharma’s Stock Climbs After FDA IND Approval & New Phase III Trial
Neuren Pharma’s FDA IND clearance and Phase III autism trial boost its market outlook, while new US patents strengthen its IP moat.
- NEUREN PHARMACEUTICALS LTD
- Australia
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read